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Abstract: Background: This systematic review aims to assess the current evidence on the efficacy
of surgical and non-surgical debridement techniques in the treatment of peri-implantitis lesions
without the use of any antimicrobials. Method: Five electronic databases (MEDLINE, Pubmed,
Scopus, CINAHL and Cochrane) were used, alongside hand searches, to find relevant articles.
Full-text articles that were randomised controlled trials, published in the English language from 2011
onwards without pre-operative, peri-operative and post-operative antibiotic usage were included.
The study was conducted according to the latest Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA)-P protocols, the latest Cochrane Risk of Bias tool and each investigated
intervention was evaluated using the grading of recommendation, assessment, development and
evaluation (GRADE) system. Results: The search yielded 2718 results. After initial screening, 38
full-text articles were assessed for eligibility. From these, 11 studies satisfied all inclusion criteria.
These 11 articles described six non-surgical and five surgical debridement therapies. Most articles
were classified as having either a high risk of bias or presenting with some concerns. Small sample
sizes, in combination with this risk of bias, meant that all interventions were adjudged to be of
either low or very low quality of evidence. Conclusion: While all investigated modalities displayed
some sort of efficacy, this review suggests that a surgical approach may be best suited to treating
peri-implantitis lesions in the absence of antibiotic therapy. Despite this weak indication, further
research is required in this field.
Keywords: peri-implantitis; decontamination; debridement; nonsurgical therapy
1. Introduction
Over the last four decades, dental implants (DI) have revolutionised the treatment of edentulous
and partially dentate patients alike. Current practice of DI placement demonstrates high success
rates [1]. Despite favourable success rates, DI are still subject to failures due to a variety of reasons.
One of the leading causes of failure is biological complications. Biological complications occur when
bacterial plaque accumulates around an implant, which consequently causes inflammatory changes in
the tissues surrounding the implant. When this inflammatory process is limited to the soft tissues, the
condition is known as peri-implant mucositis and when it spreads to the underlying alveolar bone, it is
known as peri-implantitis [2–4].
In 2017, the American Academy of Periodontology and the European Federation of Periodontology
collaborated to present an update on peri-implant diseases and conditions [5–7]. The workshop
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defined peri-implantitis as “a plaque-associated pathological condition occurring in tissues around
DI, characterized by inflammation in the peri-implant mucosa and subsequent progressive loss of
supporting bone” [5].
Clinical features of peri-implantitis lesions include the presence of bleeding on probing (BoP)
and/or suppuration on probing (SoP); increased peri-implant probing depths (PPD) and/or mucosal
recession (MR) and radiographic marginal bone loss (MBL) compared to previous examinations [5].
The prevalence of peri-implant pathology has been shown to be positively correlated to the duration
for which the implant has been in function [8]. With an increasing number of DI being placed annually,
the prevalence of peri-implantitis is expected to increase proportionally. Peri-implantitis is expected
to affect 63.4% of all patients and 30.7% of all functional DI [9]. While there have been several
clinical studies demonstrating clinical resolution of peri-implantitis lesions, a ‘gold standard’ protocol
for treatment is yet to be established [1,10]. Management of peri-implantitis lesions are based on
non-surgical and surgical approaches (Table 1).
Table 1. Treatment for peri-implantitis [11].
Treatment for Peri-Implantitis
1. Non-surgical therapy to remove local irritants from the implant’s surface with or without:
a. Surface decontamination
b. Additional adjunctive therapies
2. Surgical therapy to remove any residual subgingival deposits and reduce peri-implant pocket depths
with or without:
a. Resective Osseous therapy
b. Regenerative Osseous therapy
c. Additional adjunctive therapies [11]
Over the last decade, there have been several reviews investigating the efficacy of non-surgical
therapies [12], surgical therapies [13–15], or both [1,16–18]. Furthermore, multiple reviews have
investigated the efficacy of adjunctive treatment modalities, such as the use of dental laser [19],
air-abrasive system [20], or antibiotics [21].
However, to the best of the authors’ knowledge, there no published reviews on the efficacy of
debridement and decontamination techniques, not involving concurrent antibiotic therapy. As the
accumulation of bacterial plaque plays a critical role in the pathogenesis of peri-implantitis, the need
for implant debridement and/or decontamination to eliminate pathogenic bacterial flora becomes
obvious [11]. The use of antibiotics as an adjunctive treatment modality can have a positive effect
on treatment outcomes, however, it confounds the effectiveness of any given therapy. Of late, the
usage of antibiotics has become controversial due to a global concern around increasing antibiotic
resistance [22]; it is important to establish the most effective surgical and non-surgical debridement
and/or decontamination technique, thereby eliminating the need for exogenous antibiotic agents. Thus,
this systematic review aims to assess the efficacy of debridement and decontamination protocol, with
or without adjunctive treatment, in the absence of any exogenous antibiotic treatment in the treatment
of peri-implantitis lesions through the use of either surgical or non-surgical techniques.
2. Materials and Methods
2.1. Protocol and Registration
This systematic review was prepared in accordance with the Preferred Reporting Items for
Systematic Review and Meta-Analyses Protocols (PRISMA-P) [23] and the Cochrane Handbook for
Systematic Reviews of Interventions [24]. This review protocol has been registered with PROSPERO
(Record: CRD42019116378), as recommended by Booth et al. [25,26].
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2.2. Eligibility Criteria
The inclusion and exclusion criteria were based on the population, intervention, comparator,
outcome and study design (Table 2).
Table 2. Eligibility Criteria.
Inclusion Criteria Exclusion Criteria
Population Healthy human patients receivingtreatment for peri-implantitis lesions
Studies of human patients with chronic diseases,
co-morbidities and non-human studies; Animal
studies
Intervention
Surgical or non-surgical treatment of
peri-implantitis lesions, including
adjunctive treatment
Studies which allow/use pre-operative (up to 3
months prior to initiation), peri-operative and
post-operative anti-microbial therapy
Comparator
Individuals or teeth within the same
individual (including split mouth
technique) not subjected to the same
therapeutic variable
Outcome
Resolution of peri-implantitis, including
implant survival and absence of
peri-implant probing pocket depths of >5
mm, suppuration, bleeding on probing
(BoP) and further bone loss
Studies including patients who have previously
received peri-implantitis treatment
Study Design Randomised controlled trials (RCT),published or unpublished
Non-RCT, cohort studies, case reports, case series,
reviews, abstracts, systematic reviews, opinions,
studies with questionnaires or studies where the
diagnosis/measurement of peri-implantitis was
performed only on radiographs rather than clinically.
2.3. Information Sources, Search Strategy and Study Selection
Five electronic databases, MEDLINE, PubMed, Cochrane Library, CINAHL and Scopus, were
searched using Medical Subject Headings (MeSH) terms, key words and Boolean operators. Searches
did not have any limitations placed on them to enable the widest pool of studies to be captured. The
search strategy for Medline is presented in Table 3. The full electronic search strategy is accessible on
PROSPERO (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019116378).
Table 3. Search Strategy for Medline via OVID.
# Searches Results
1 exp Peri-implantitis/ 1017
2 exp Therapeutics/ 4,367,916
3 exp Operative Surgical Procedures/ 2,990,228
4 2 OR 3 6,056,211
5 1 AND 4 453
Eight journals (Journal of Clinical Periodontology, Journal of Periodontology, International Journal
of Implant Dentistry, Clinical Implant Dentistry and Related Research, Clinical Oral Investigations,
Clinical Oral Implants Research and Implant Dentistry) were selected to conduct manual searches to
ensure that additional articles were not missed in the electronic search. The World Health Organization’s
International Clinical Trials Registry Platform and Clinical trials database (Clinicaltrials.gov) were
scanned to identify any relevant ongoing trials. Grey literature databases such as Opengrey and
System for Information on Grey Literature in Europe was also searched for any relevant grey literature.
Reference lists of review articles and all included studies were checked for any further articles of
relevance. A reference management software (Endnote version X8; Clarivate Analytics, Philadelphia,
PA, USA) was used to sort the results and remove duplicates. Searches were initiated in June 2019
(Figure 1).
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Relevant full-text articles were identified through their titles and abstracts, before being further
assessed according to the pre-specified inclusion and exclusion criteria. Data extraction of included
studies was then conducted and collated into a table format.
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2.4. Risk of Bias (RoB) in Individual Studies
The 2019 Cochra e Collaboration bias assessment tool was used to assess the RoB of included
studies [24]. This tool allowed analysis of each study across five key domains to adjudge each study as
having either low, concerning or high RoB.
2.5. Data Synthesis: Evaluating the Effect of the Intervention
The primary end-point of interest with these studies was to find the intervention which causes the
greatest resolution of peri-implantitis lesions. To assess this, the association/difference between different
modalities and successful treatment outcomes were compared. The Grading of Recommendations,
Assessment, Development and Evaluations (GRADE) approach was used to assess the quality of
evidence for each treatment modality [27]. The parameters used in the GRADE approach (RoB,
inconsistency, indirectness, imprecision or publication bias) were downgraded by one level wherever
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serious concern was found. An overall quality of evidence (high, moderate, low or very low quality)
could then be adjudged.
2.6. Additional Analysis
Cohen’s kappa statistic was used to determine the inter-rater agreement between review authors
during article selection and RoB and GRADE assessments.
3. Results
3.1. Literature Search and Screening Process
Using the search strategy described above, 2718 articles were found. After removing duplicates
and the addition of five additional hand-searched articles, title and abstract evaluation resulted in 38
full-text articles meeting pre-specified inclusion and exclusion criteria. Following further evaluation,
it was determined that 11 articles [28–38] satisfied all criteria for inclusion. No unpublished studies
of relevance were found in ongoing trials, or grey literature searches. Inter-reviewer agreement for
inclusion of articles was quite high (k = 0.873). Figure 1 depicts the PRISMA flowchart showcasing the
literature selection process, adopted to the recommendations of Vu-Ngoc et al. [39].
3.2. Study Characteristics
The included studies were all published between 2011 and 2019. While no restrictions had been
placed on the search, these parameters were placed to coincide with the last major systematic review
published in this field [1]. The previous review included studies up until 2011, so to ensure that
no studies in this year were missed, this review incorporates all studies published in 2011. Of the
included 11 studies, six reported usage of non-surgical techniques [28–33] and five reported on surgical
techniques [34–38].
3.2.1. Non-Surgical Techniques
Investigated non-surgical treatment modalities included have been listed in Table 4.
Table 4. Non-surgical treatment modalities.
1. Mechanical debridement versus adjunctive diode laser application [28]
2. Mechanical debridement + topical chlorhexidine (CHX) application versus air-abrasive device containing
amino acid glycine powder [29,32]
3. Mechanical debridement + matrix chips vs. mechanical debridement + CHX chips [30]
4. Er: YAG laser versus air-abrasive device containing hydrophobic powder [33]
5. Mechanical debridement versus adjunctive local applications of chloramine gel [31]
Adjunctive treatments to mechanical debridement were investigated in three studies, including
the use of chloramine gel [31], diode laser application [28] and chlorhexidine chips [30].
After a 3-month follow up, Roos-Jansaker et al. found no statistically significant difference between
conventional manual debridement (usage of ultrasonic and hand-scalers) and the adjunctive use of
chloramine gel in the treatment of peri-implantitis across any of the studied parameters. Despite such an
indifference between the groups, both groups resulted in significantly improved clinical outcomes [31].
Similarly, Arisan et al. found no statistically significant differences between conventional debridement
and the adjunctive use of a diode laser across many of the studied parameters, including, mean and
deepest PPD, plaque index (PI) and BoP. Both modalities showed a statistically significant difference
across these parameters from baseline to the study’s conclusion at six months. Marginal bone loss
(MBL) was the one parameter where a significant difference was found between the groups, with
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participants in the laser group revealing greater MBL at the end of the six months as compared to the
control, despite no baseline differences [28].
Machtei et al. evaluated the effectiveness of a proposed treatment protocol for
peri-implantitis lesions, whereby participants were subjected to intensive repeated applications
of chlorhexidine-containing chips in affected sites, as an adjunctive measure to conventional
debridement [30]. Patients were randomised to receive either hydrolysed gelatine matrix chips
(MatrixC) or a biodegradable matrix containing chlorhexidine chips (PerioC®®; Dexcel Pharma,
Or-Akiva, Israel). Clinical measurements and chips placements were repeated at weeks 2, 4, 6, 8, 12 and
18 post-intervention, with the participants then returning after 6 months for a final assessment. The
study reported that the PPD improvement in the PerioC group was greater than that of the MatrixC
group, being borderline significant (p = 0.07, mixed model). Clinical attachment level (CAL) gain was
also found to be significantly greater in the PerioC group, as compared to the MatrixC group. No
in-between group differences were found when measuring BoP, and both groups resulted in significant
improvements across all parameters over the 6-month follow up period. Hence, the authors concluded
that frequent placement of PerioC and MatrixC, alongside conventional debridement, resulted in
substantial improvement in sites affected by peri-implantitis [30].
Three studies investigated the use of air-abrasive devices as a treatment modality, with two
comparing them to conventional debridement alongside local chlorhexidine application [28,30], and
the other comparing them to an Er:YAG laser application [31].
John et al. found that air-abrasive devices resulted in a significantly higher decrease in mean BoP
scores as compared to conventional debridement. However, this result was an anomaly as there were no
differences reported across PI, PPD, MR or CAL gains between groups. The study concluded that both
treatment options resulted in comparable and significant CAL gains at the end of the 12-month study
period, with air-abrasive devices resulting in a greater reduction in BoP [29]. Sahm et al. investigated
identical interventions and reached comparable conclusion with their study [32]. They conducted
clinical measurements at 3-month and 6-month follow-ups and found that the air-abrasive device group
had significantly lower BoP than the conventional debridement group in both time groups, however,
there were no other differences across parameters like PI, MR, PPD or CAL gains [32]. Renvert et
al. investigated the efficacy of an air-abrasive device as compared to an Er:YAG laser. They found
that both therapies allowed statistically significant improvements across all measured parameters,
including, BoP, SoP, PI, PPD and MBL. However, they also concluded that there were no inter-group
differences between the two treatments across any of the parameters [33].
3.2.2. Surgical Techniques
Investigated surgical treatment modalities have been listed in Table 5.
Table 5. Surgical treatment modalities.
1. Resective surgery + apically positioned flap + bone recontouring + sterile saline versus resective surgery
+ apically positioned flap + bone recontouring + 35% phosphoric acid [34]
2. Regenerative surgical treatment versus regenerative surgical treatment + enamel matrix derivative [35]
3. Access flap + plastic curette debridement + saline versus access flap + plastic curette debridement +
diode laser [36]
4. Resective surgery + apically positioned flap + bone recontouring + debridement + placebo versus
resective surgery + apically positioned flap + bone recontouring + debridement + 0.12% CHX + 0.05%
cetylpyrinidium chloride (CPC) [37]
5. Resective surgery + apically positioned flap + bone recontouring + debridement + 0.12% CHX versus
resective surgery + apically positioned flap + bone recontouring + debridement + 2% CHX [38]
A combination of resective surgery, an apically positioned flap, bone recontouring and use of
either saline [34], placebo [37] or 0.12% CHX and 0.05% CPC solution [38] was investigated in three
separate studies. These studies compared this treatment to the additional usage of 35% phosphoric
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acid [34], combination of 0.12% CHX and 0.05% CPC [37], as well as a stronger 2% CHX solution,
respectively [38].
Hentenaar et al. found that adjunctive application of 35% phosphoric acid led to greater immediate
reduction in total anaerobic bacterial counts on the implant surface, as well as a significantly lower
count of culture-positive DI [34]. Despite showing effective decontamination of the implant surface,
phosphoric acid did not present with significantly better clinical or microbiological measurements after
the 3-month follow up period, as compared to the control [34]. Similarly, de Waal et al. reported that
the adjunctive use of 0.12% CHX + 0.05% CPC resulted in a significantly greater reduction in bacterial
load on the implant surface, but did not translate into better clinical results across a 12-month follow up
period [36]. The control in this study was a placebo solution [37], and in 2015, de Waal et al. conducted
another study, which used the 0.12% CHX + 0.05% CPC as a control to a stronger 2% CHX solution [38].
This study found no significant difference for either microbiological or clinical measurements between
the two groups over a 12-month follow-up period. Hence, the authors concluded that a 0.12% CHX +
0.05% CPC successfully reduces anaerobic bacterial load on the implant surface better than debridement
alone, but this does not translate to better clinical therapeutic outcomes [38].
Papadopoulos et al. conducted a randomised controlled trial (RCT) investigating the efficacy of
using a diode laser as adjunctive treatment to surgical debridement [36]. They performed measurements
at baseline, 3 months and 6 months post-intervention. PPD reduction, BoP changes and PI reduction
were significant across both groups within the study but did not vary between groups. However,
CAL gain was found to be significantly better in the laser group, as compared to the control. The
authors concluded that both therapies were equally effective in reducing PPD, BoP and PI, whereas
CAL improvement was more associated with the adjunctive use of a diode laser [36].
Isehed et al. investigated the usage of regenerative surgical treatment to treat peri-implantitis
lesions, with or without adjunctive enamel matrix derivative (EMD), over a five-year follow-up
period [35]. There were no significant differences between the groups at baseline across any of the
measured parameters, including, BoP, SoP and MBL. At the conclusion of the study, there were no
significant differences between the test group or the control group across any of the aforementioned
parameters. At the end of the 5-year period, four of 13 (31%) DI were either lost or retreated due
to infection in the EMD group, compared to seven of 12 (58%) in the non-EMD group. Univariate
comparisons listed this as an insignificant difference (p = 0.48), so the authors ran a partial least square
modelling, as this was deemed to be better for smaller samples. Through this model, they were able to
conclude that EMD treatment was positively associated with implant survival up to 5 years, but larger
studies are required in this field [35].
Tables 6 and 7 provide a summary of the characteristics of included studies, including each
study’s diagnosis of peri-implantitis, number of DI included, interventions, follow-up period, clinical
parameters investigated and a summary of the main results.
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PPD—peri-implant probing depth; BoP—Bleeding on Probing; SoP—Suppuration on Probing; MBL—Marginal Bone Loss; CAL—Clinical Attachment Loss; PI—Plaque Index.
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3.3. Data Analysis
Due to the methodological and clinical heterogeneity across included studies, data pooling was
not possible. Hence, a narrative synthesis rather than a meta-analysis was conducted.
3.4. Risk of Bias
Of the 11 included studies, seven had a low risk of bias in domain one [29,30,33–35,37,38], relating
to the randomisation process, as opposed to four which presented with some concerns [28,31,32,36],
usually due to non-disclosure of critical information.
Regarding the second domain, dealing with deviation from intended intervention, four studies
were adjudged to have a high risk of bias [29,31,35,36], two with some concerns [32,34] and five with a
low risk [28,30,33,37,38]. High risk was generally associated with a lack of appropriate analysis to deal
with missing data and a likely potential of failure to analyse missing data having a significant impact.
If the potential of failure to analyse missing data was unlikely to have a significant effect on the studies’
results, then the study was classified as having ‘some concerns.’
Domain three deals with the risk of bias due to missing outcome data. Out of the 11 studies, nine
were adjudged to have a low risk of bias [28–34,37,38], whereas two presented with high risk [35,36].
These studies had a large percentage of participants lost and it was seen to be likely that missingness in
the outcome depended on its true value. The fourth domain investigated the risk of bias in measurement
of the outcome. Nine of the 11 studies had a low risk of bias in this domain [28–30,32–34,36–38],
whereas one caused some concerns [31], and one had high risk [35]. Some concerns were brought
about due to the possibility of the outcome being influenced by the knowledge of intervention received,
and there was no information reported on whether outcome assessors were aware of the intervention
received. However, in the study conducted by Roos-Jansaker et al. [31], it was unlikely that this would
have been the case, hence, the study was classified as having some concerns. On the other hand, study
by Isehed et al. had different examiners performing clinical measurements, hence measurements could
have varied, which resulted in them being adjudged as having a high risk of bias [35].
Finally, the fifth domain referred to the risk of bias in selection of the reported result. Only one
study was adjudged as having some concerns in this regard [28], whereas all the others had low
risk [29–38]. In Arisan’s study, the method specifies the usage of ANOVA for the MBL and PPD values,
however, the results only show the MBL values and not the PPD values [28].
Overall, four studies had a low risk of bias [30,33,37,38], three had some concerns [28,32,34] and
four had a high risk [29,31,35,36]. These results are depicted in Table 8.
Table 8. Cochrane Risk of Bias Tool.
Study/Domain Domain 1 Domain 2 Domain 3 Domain 4 Domain 5 Overall
Arisan 2015 Concerns Low Low Low Concerns Concerns
Hentenaar 2017 Low Concerns Low Low Low Concerns
Isehed 2018 Low High High High Low High
John 2015 Low High Low Low Low High
Machtei 2012 Low Low Low Low Low Low
Papadopoulos 2015 Concerns High High Low Low High
Renvert 2011 Low Low Low Low Low Low
Roos-Jansaker 2017 Concerns High Low Concerns Low High
Sahm 2011 Concerns Concerns Low Low Low Concerns
De Waal 2013 Low Low Low Low Low Low
De Waal 2015 Low Low Low Low Low Low
3.5. Quality of the Evidence
The GRADE tool was utilised to ascertain the overall quality of evidence provided, through the
assessment of criteria including risk of bias, inconsistency, indirectness, imprecision and publication
bias. Four interventions were adjudged to have presented a low quality of evidence, whereas the other
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nine were all very low quality. Due to this, the true effect of an intervention is likely to be substantially
removed from the estimated effect for most interventions. These results, alongside reasons for these
judgements, are denoted in Table 9. There was a high agreement amongst reviewers regarding the
GRADE assessment, reflected in a kappa value of 0.839.
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Single study reports that CHX chips
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Single study reports that matrix chips





+ Air-abrasive device 48 (3 studies) Very Serious
1 Not serious Not serious Serious 3 Suspected 4






+ chloramine gel 16 (1 study) Very Serious
1 Not serious Not serious Serious 3 Suspected 4
Single study reports improvements in
some clinical parameters surrounding
peri-implantitis lesions, however, no
group difference was found between
conventional debridement and
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⊕###
VERY LOW











+ chlorhexidine application 28 (2 studies) Very Serious
1 Not serious Not serious Serious 3 Suspected 4






+ 0.12% CHX and 0.05%
CPC
80 (2 studies) Not serious Not serious Not serious Serious 3 Suspected 4
All studies report positive changes





+ 2% CHX 49 (1 study) Not serious Not serious Not serious Serious
3 Suspected 4
Single study reported positive changes
across several indicators of
peri-implantitis, however, no significant
difference between solutions of 2% CHX
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The outcome of interest: resolution of peri-implantitis (for which a single pooled effect estimate was not available and only a narrative synthesis of the evidence was provided).
NOTE: As the outcome for all interventions was the resolution of peri-implantitis lesions, individual GRADE Summary of Findings tables were collated into a single table for publication
purposes. GRADE Working Group grades of evidence. High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate certainty: Further
research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low certainty: Further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to change the estimate. Very low certainty: Any estimate of effect is very uncertain. 1 The evidence was downgraded by two
levels because of very serious concern regarding the risk of bias; one or more included studies have high risk of bias. 2 The evidence was downgraded by one level because of serious
concern regarding the risk of bias; one or more included studies have raised some concerns regarding risk of bias. 3 The evidence was downgraded by one level because the results came
from small studies and numbers of participants, with insufficient event rates for dichotomous and continuous outcomes. 4 The evidence was downgraded by one level because of results
came from small studies with small numbers of participants.
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4. Discussion
In 2018, Ting et al. conducted a systematic review of peri-implantitis-related systematic reviews
and meta-analyses, in order to provide a comprehensive overview of peri-implantitis [40]. This review
concluded that “no strong evidence was found to suggest the most effective treatment intervention for
peri-implantitis, although most peri-implantitis therapies can produce successful outcomes” [40].
In recent decades, it has become critical that clinicians limit their prescription of systemic antibiotics
to deter the development of antibiotic resistance and super-infections [22,41]. Adjunctive systemic
antibiotic usage has been suggested as a therapeutic measure for peri-implantitis lesions, however,
their benefit is questionable [42,43]. Despite their usage, retreatment is often required, indicating
that their usage should be restricted [44,45]. In light of these findings, such a systematic review was
conducted to allow clinicians to appreciate the most effective debridement and/or decontamination
techniques in treating peri-implantitis lesions.
4.1. Overall Completeness and Applicability of Evidence
Of the eleven included studies, four were deemed to have a high risk of bias [29,31,35,36] and
three presented with certain concerns [28,32,34]. The completeness of all studies will be discussed
across the following parameters in order to help clinicians better evaluate these RCTs:
4.1.1. Inclusion Criteria
In their systematic review encompassing studies from 1950 to 2011, Esposito et al. reported that
some of their included studies did not adequately describe the initial degree of pathology around
included DI, particularly regarding MBL [1]. Some studies had to be as they failed to distinguish
between peri-implant mucositis and peri-implantitis, thus confounding the results. However, this
was not an issue in this review, as all studies had clearly defined their diagnostic determinants of
peri-implantitis, and all included some form of bone loss. This could possibly be due to the greater
knowledge available surrounding this topic in later years [2,3].
4.1.2. Exclusion Criteria
To be a part of this review, any studies in which patients had been prescribed antibiotics
pre-operatively, peri-operatively or post-operatively were excluded. Apart from this, common
exclusions included: patients with a history of periodontitis, systemic diseases which can affect
peri-implantitis treatment (uncontrolled diabetes, osteoporosis, cardiovascular diseases etc.) [28–38];
some studies also excluded smokers [27,30]. While Esposito et al. suggested that such strict exclusion
criteria may limit the extrapolation of the findings to a broader population [1], it does help in reducing
confounders to the treatment and evaluating the efficacy of the studied interventions.
4.1.3. Outcome Measures
While the main outcome measure for successful treatment of peri-implantitis lesions could be
implant retention, it was only specifically reported as an outcome measurement in one study [35]. On
the other hand, MBL is regarded as the most reliable prognostic tool for treatment, but it was only
used as an outcome measurement in one non-surgical study [26] and three surgical studies [35,37,38].
These results are strikingly similar to the findings of Esposito et al. [1] suggesting that the exploration
of implant failure and MBL could be better used as outcome measurements in trials of this nature.
4.1.4. Interventions
Several interventions were investigated in the included studies. Most had been suggested from
previous clinical experience trying to parallel treatment of peri-implantitis with the treatment of
periodontitis. In this case, all included trials involved appropriate interventions and most studies
provided a justification for their choice of intervention. It has been suggested that extensive treatment
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may confound treatment outcomes, making it difficult to distinguish between effective and non-effective
components of treatment [1]. Some studies had funding from the manufacturers of the interventions
that they employed [29,31–33], while others had instruments supplied from the manufacturer [38]
or had been part of the manufacturer’s research and development team [30]. However, none of the
studies explicitly declared a conflict of interest [1].
4.1.5. Sample Sizes
Sample sizes across most studies included in this review were small, with the largest study
managing to recruit 60 patients [30] and the smallest study recruiting 18 patients [31]. With an
increasing proportion of individuals being rehabilitated with DI, and DI being in function for an
increased number of years, the number of patients who are affected by peri-implantitis will inevitably
increase in absolute terms. Hence, future studies must aim to recruit higher numbers of individuals
and eligible implant sites to provide higher levels of evidence with minimal risk of bias.
4.1.6. Randomisation and Blinding
To ensure highest level of evidence is being investigated, it is critical that authors of RCTs
clearly outline their randomisation techniques and ensure blinding of participants and clinicians to
the highest possible degree. As four studies in this review failed to reveal the exact nature of their
blinding [28,31,32,36], they were adjudged to have some concerns regarding their risk of bias. More
strenuous effort is required to ensure that appropriate study designs are being implemented.
4.1.7. Follow-Up
Peri-implantitis is a chronic disease, with an increased risk for those DI which have been in
function for greater than five years. Its treatment is also long-term and needs to be followed-up for a
long period of time. Most studies included in this review only had follow-up periods of 6–12 months,
which is a relatively short follow-up time for such a chronic disease; two trials had a follow-up of
just 3 months [31,34]. Only one study had a follow-up period of longer than 12 months, which was
5 years [35]. Studies with higher follow-up periods are vital in evaluating the long-term effects of
treatment modalities.
4.1.8. Statistical Analysis
Most studies included in this review included DI as the unit of statistical analysis, rather than
the number of patients. This poses an issue, as patient factors play a critical role towards successful
treatment. Treatment outcomes of multiple implicated DI in a single patient are dependent on multiple
factors, including patient’s oral hygiene, design of the prosthesis, systemic health and smoking
status [1]. It has been suggested that trials adopt a split-mouth or parallel group design or include the
clustering of DI within a patient during the analysis. Multilevel modelling has been suggested as a
method to carry out such a statistical analysis [1]. Most studies included in this review performed
some form of multilevel modelling, being able to adjust for confounders and trying to find associations,
which is an improvement from previous reviews.
4.1.9. Drop Outs, Withdrawals and Failures
Patients being lost to follow-up is a common occurrence in clinical studies. However, there is
a requirement that any patient lost due to any reason, should be accounted for and reported in the
final report. In this case, if treatment fails, and further treatment is required, or an explantation is
required, this must be reported and appropriately accounted for in the statistical analysis. Most studies
in this review often excluded any individuals who had failing DI from their final calculations and
did not have appropriate statistical methodology to account for the missing data. Due to this reason,
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several studies were found to have a high risk of bias [29,31,35,36], or at least some concerns [32,34],
downgrading their reliability.
4.2. Quality of the Evidence
While this review has been conducted to ensure that the highest-level of evidence is included
and assessed, it has become apparent that there is a lack of high-quality clinical trials in this area. All
interventions have been assessed as being of low or very low quality of evidence, suggesting that
the true effect of each intervention may be substantially different from the estimated effect. Of the
evaluated interventions, only four interventions were deemed to be of low quality, rather than very
low quality. These interventions included:
1. Non-surgical debridement + CHX chips;
2. Non-surgical debridement + matrix chips;
3. Surgical resective treatment + 0.12% CHX and 0.05% CPC;
4. Surgical resective treatment + 2% CHX.
These interventions came from three out of the eleven investigated studies [30,37,38], showing a
poor quality of evidence compared to eight other studies [28,29,31–36]. These low-quality interventions,
like all the others, also suffered from a downgrade due to low sample sizes and publication bias. In
this GRADE analysis, number of DI has been utilised as a unit, but if patients were used, the sample
sizes would be even lower. The need for higher sample sizes to ensure that high-level evidence
has been employed is vital if a true gold standard therapy for peri-implantitis debridement and/or
decontamination is to be ascertained.
4.3. Practical Implications
4.3.1. Non-Surgical Therapies
The adjunctive use of chloramine gel as a decontaminant was equally as effective as non-surgical
debridement therapy alone, resulting in statistically significant clinical improvements for a follow-up
period of 3 months [31]. The study recruited 18 individuals with at least two DI impacted by
peri-implantitis and exposed one to the control and one to the test. This low sample size, combined
with a short follow-up period of 3 months, and the fact that an appropriate analysis was not used
to estimate the effect of assignment led to the study being adjudged to have a high risk of bias, as
well as very low-quality evidence for both interventions. There is scope for further research in this
field, preferably an independent study, with a larger number of participants, clearer methodology and
longer follow-up period.
Machtei et al. investigated the efficacy of repeated applications of matrix (MatrixC) and
chlorhexidine-containing chips (PerioC) following non-surgical treatment [30]. They reported that the
PerioC led to a mean PPD reduction of 2.19 mm, as compared to 1.59 mm in MatrixC, and a CAL gain
of 2.21 mm as compared to 1.56 mm in the MatrixC group. Both parameters were significantly better in
the PerioC group, however, there were no group differences in the BoP over the 6-month follow-up
period. The authors reported that this was a better than expected result [30], as a meta-analysis of
non-surgical treatment had concluded that a mean PPD reduction of 0.77 mm and CAL gain of 0.79
mm can be expected from non-surgical therapy [46]. Machtei et al. also predicted that the significant
improvement in the MatrixC group suggested that the matrix degradation itself had an antibacterial
effect [30]. This study was adjudged to have a low risk of bias, and hence the interventions presented
were rated as low-quality evidence, being penalised for small sample sizes. Despite this, the study was
well conducted and presented with positive results, which will require further evaluation.
Arisan et al. found that the adjunctive use of a diode laser was equally as effective across most
clinical parameters, as compared to the control, but was found to have led to higher MBL than the
control group, despite there being no difference at baseline [28]. The authors suggest that this could
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be due to several factors, including, individual host response, confounding factors in the healing
mechanism of the peri-implant alveolar bone, or even a negative impact of the diode laser. It has
been suggested that excessive thermal damage due to the laser application might jeopardize healing
conditions [47,48]. The authors had tried to be mindful of this, by utilising a low-powered 810 nm
diode laser, which has previously been shown to be innocuous on the implant surface [49], on top of
utilising similar methodology to previous studies, but cannot rule out this possibility. Unfortunately,
their small sample size and concerning risk of bias assessment means that both interventions were
assessed to be of very low quality [28], hence, their results cannot be used for a generalised conclusion.
Prior to study conducted by Arisan et al., a systematic review investigated the effect of various
laser wavelengths in the treatment of peri-implantitis [50]. They reported that non-surgical laser
treatment with a single application of either the Er:YAG (2940 nm) laser or a diode (660 nm) laser
in combination with a phenothiazine chloride dye was efficient in controlling inflammation around
treated DI for at least 6 months following intervention. However, this treatment had limited effects on
reduction in PPD and gain in CAL. Based on this, the authors cautiously concluded that laser treatment
may be further investigated as phase 1 therapy for the treatment of peri-implantitis, but based on their
findings, no superiority of laser treatment above conventional treatment could be found.
Renvert et al. investigated the efficacy of an Er:YAG laser against an air-abrasive device [33].
They found that both treatment outcomes were equally effective in reducing peri-implantitis across
the measured parameters, but no statistically significant differences between the groups were evident.
While there were little group differences, they found that the overall clinical improvement across
both modalities was limited, and hence, concluded that both treatment modalities are insufficient to
treat deep peri-implantitis defects. The authors suggested that this may be due to the severity of the
disease and further studies would need to be conducted to determine whether there are threshold
levels beyond which non-surgical intervention is ineffective. They also acknowledged that another
possibility could include tissue trauma for the treatment, but this was unlikely as they used laser
settings below defined risk values [51], as well as a protocol for appropriate usage of the air-abrasive
device in periodontal pockets [52], and no serious adverse events were recorded across either group.
The authors acknowledged that the lack of eligible participants is a chronic issue in clinical dentistry
research, but otherwise, this study was assigned a low risk of bias. However, due to the methodology
of other studies investigating the same interventions, both interventions’ overall GRADE were of a
very low quality.
Both studies by Sahm et al. and John et al. investigated the efficacy of air-abrasive devices against
the control of manual debridement and local application of chlorhexidine. Both studies reached the
same conclusion, with both treatment modalities being similar in their efficacy across PPD reductions
and CAL gains, but the air-abrasive device leading to a statistically greater suppression of BoP. This
parallels the conclusion drawn by the systematic review conducted by Shwarz et al. regarding the
efficacy of air polishing for the non-surgical treatment of peri-implant diseases [22]. Sahm et al. put this
effect down to the increased effectiveness of air-abrasive devices over manual debridement in removing
bacterial plaque biofilms [53–55], hence, reducing bacterial load and leading to lower BoP scores.
The use of non-surgical manual debridement with chlorhexidine disinfection revealed limited
clinical efficacy in controlling disease progression, in line with other studies of the same nature [56,57].
Sahm et al. [32] differentiated their results from Renvert et al. [33] who reported that air-abrasive
devices fared no better than Er:YAG laser treatment, by pointing out that Sahm et al. included patients
suffering from initial to moderate peri-implantitis, rather than severe peri-implantitis. This suggests
that the efficacy of non-surgical treatment with adjunctive air-abrasive devices may be limited to a
threshold level. John et al. proved that these results could be maintained for 12 months, although both
studies suffered from concerns and a high risk of bias, respectively. All these studies were industry
funded. This fact, alongside the high risk of bias and small sample sizes, resulted in the intervention
being graded as very low-quality.
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4.3.2. Surgical Therapies
Hentenaar et al. compared the adjunctive 35% phosphoric acid to resective therapy and
decontamination with saline solution [34]. While they found that the test group led to a significantly
greater immediate suppression of anaerobic bacterial counts on the implant surface, this did not
translate into better clinical results or even microbiological results by the end of the three-month follow
up period. The authors chose phosphoric acid as a decontaminating agent as acids with low pH have
been reported to exert a potent bactericidal effects [56,57], and have an innocuous effect on the titanium
implant surface [58]. While their study found that the adjunctive usage of 35% phosphoric acid had no
net positive or negative effect on top of surgical resective treatment, the authors hypothesised that
surface damage of dental alloys may potentially be induced after detoxification with acidic solutions,
hindering re-osseointegration. Wheelis et al. reported noticeable morphological changes and corrosion
on the titanium surface when the synergistic effect of acidic environments and mechanical forces were
investigated, as opposed to neutral and basic treatments [59]. There were concerns regarding risk of
bias in this study, in combination with a small sample size and a short follow-up period of 3 months,
accumulating in both interventions ultimately being graded as being of very low quality.
Similarly, de Waal et al. discovered that a 0.12% CHX + 0.05% CPC solution lead to greater
reduction in bacterial load on the implant surface, but this did not translate into a better clinical or
radiographical results over the 12-month follow-up [37]. They compared this to the results of Schwarz
et al. who also found that the method of surface debridement and decontamination did not impact the
clinical outcomes following combined surgical therapy of advanced peri-implantitis lesions [60,61].
The authors suggested that the long-term stability of clinical outcomes may be influenced by factors
other than the method of decontamination. The authors chose to use a combination of 0.12% CHX
and 0.05% CPC non-alcoholic solution in this study as it has been reported to be an equally effective
anti-plaque and anti-inflammatory agent as the 0.2% CHX solution with alcohol [62]. In 2015, de
Waal et al. extended their research by comparing the efficacy of 2% CHX solution against 0.12% CHX
+ 0.05% CPC adjunctive to resective surgical treatment [38]. They found no significant differences
between either group over three follow-up periods (3, 6 and 12 months) over microbiological or clinical
parameters, despite both being effective. The authors concluded that despite the 2% CHX solution not
causing any detrimental clinical effects, it neither contributed to improved clinical or radiographic
outcomes, despite being over 16 times the strength of the control solution, suggesting a threshold level
for efficacy. Both studies were assessed to have a low risk of bias and were adjudged to be of low
quality only due to the small sample sizes for each intervention.
Papadopoulos et al. investigated the adjunctive use of a diode laser to surgical treatment and
discovered that the diode laser results in a significantly greater CAL, but no other significant advantage
over surgical treatment [36]. Both treatments were equally effective across all other parameters and
hence the authors concluded that the additional use of a diode laser offers limited clinical benefit. The
authors suggested several confounding variables which could contribute to a variety of non-comparable
results across studies of similar nature, including type of lasers, frequency of laser irradiation, different
kinds of peri-implantitis lesions, removal of supra-structures and application of implantoplasty. Despite
this result, this study’s high risk of bias, combined with small sample size resulted in both interventions
being assessed as being of very low quality.
Isehed et al. investigated the efficacy of surgical regenerative treatment over an extended follow-up
of 5-years [35]. They concluded that adjunctive enamel matrix derivative (EMD) usage was positively
associated with implant survival. The authors acknowledged that the removal of DI with the most
advanced bone loss probably influenced the results, despite there being a significant increase of
approximately 1 mm of bone after 5-years across both groups. They also discovered that some changes,
seen at the 1-year follow-up, disappeared at the consequent 3-year and 5-year follow-ups, suggesting a
single treatment may not be sufficient to ensure a stable long-term result [63,64]. In the EMD group,
11/13 DI (84.6%) survived compared to 9/12 in the non-EMD group (75%). The authors predicted that
this could be due to EMD-induced early healing and an additional anti-microbial effect [65,66]. Despite
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a long-term follow-up unlike most other studies included in this review, this study suffered from a
high risk of bias, small sample size and hence was adjudged to present very low-quality evidence.
5. Conclusions
As an increasing proportion of the global population gets edentulous spaces rehabilitated by DI,
the absolute incidence of peri-implantitis is expected to rise. With an ever-increasing global threat
of super-infections and antibiotic resistance, it is essential that treatment which minimises harmful
excessive usage of antibiotics is adopted. Hence, the need to study the efficacy of techniques used to
manage peri-implantitis lesions without antibiotics is critical.
Despite this, the standard of research that is being presented in this field is currently lacking in the
quality needed to make assertive conclusions about the efficacy of any treatment. With many studies
lacking appropriate methodological quality, lengthy follow-up periods and large sample sizes, it is
difficult to rely upon the results of the studies that have been published in this field.
The current review suggests that a surgical approach to treating peri-implantitis lesions in the
absence of antimicrobial therapy may have greater efficacy than a non-surgical approach. Despite this
weak indication, the authors of this review recommend further investigation of both approaches and
adjunctive measures to determine the best treatment protocol for managing peri-implantitis lesions.
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